Problem statement: what are the key issues in treating early stage HL?

A. Engert

New scenario for frontline advanced stage HL

A. Younes

Managing risk in advanced stage HL

A. Engert

Treatment approaches in relapsed/refractory HL: Brentuximab vedotin

A. Younes

Treatment approaches in relapsed/refractory HL: Anti-PD1

A. Engert

Treatment approaches in relapsed/refractory HL: Anti-PDL1

R. Chen

Second generation BTK inhibitors: Acalabrutinib and BGB-3111

C. Tam

BTK inhibitors and BCL-2 antagonists

C. Tam

Changing treatment landscape in relapsed/refractory patients: novel targets and new strategies

W.H. Wilson

The role of CAR T-cells

S.S. Neelapu

New scenario and concepts in front-line treatment for young patients

A. Younes

The complexities in relapsed/refractory setting: Ibrutinib and second generation of BTK inhibitors

S. Rule

The complexities in relapsed/refractory setting: Combination of ibrutinib and venetoclax

C. Tam